Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05232838 · ClinicalTrials.gov registry record · NA

US Pilot Study of the CereVasc® eShunt® System in Normal Pressure Hydrocephalus

A NA study of Hydrocephalus and Hydrocephalus, Normal Pressure, sponsored by CereVasc.

Active
Registry status
NA
Development phase
50
Enrollment target
11
Study locations

NCT05232838 is a NA study of Hydrocephalus and Hydrocephalus, Normal Pressure that is active but no longer recruiting, run by CereVasc. The registered enrollment target is 50 participants, below the 130-participant average among 17 other Hydrocephalus trials with a reported enrollment target (62% lower). The trial reports 11 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05232838, a NA study of Hydrocephalus and Hydrocephalus, Normal Pressure, is active but no longer recruiting, sponsored by CereVasc.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
50 participants
Enrollment target
11
Study locations

Study Summary

The eShunt® System is a minimally invasive method of treating communicating hydrocephalus. The eShunt System includes a proprietary eShunt Delivery System and the eShunt Implant, a permanent implant deployed in a minimally invasive, neuro-interventional procedure. The eShunt System is intended to shunt cerebrospinal fluid from the intracranial subarachnoid space to the venous system for the treatment of patients with normal pressure hydrocephalus, reducing disability due to symptoms including one or more of gait disturbance, cognitive dysfunction and urinary incontinence.

Conditions Studied

Hydrocephalus Hydrocephalus, Normal Pressure

Interventions

  • DEVICE eShunt Implant

Study Locations (11)

New York

  • University at Buffalo, - Buffalo
  • NYU Langone Health - New York
  • University of Rochester Medical Center - Rochester
  • Montefiore Medical Center - The Bronx

Connecticut

  • Yale University - New Haven

Florida

  • Baptist Health - Jacksonville

Kansas

  • University of Kansas Medical Center - Kansas City

Kentucky

  • University of Kentucky Research Foundation - Lexington

Massachusetts

  • Beth Israel Deaconess Medical Center - Boston

Rhode Island

  • Rhode Island Hospital - Providence

Virginia

  • Virginia Commonwealth University - Richmond

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2022-04-20
Est. Completion 2030-06-30
Phase NA

Sponsor

CereVasc

3 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05232838

The ClinicalTrials.gov registry entry for NCT05232838 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 130-participant average among 17 other Hydrocephalus trials with a reported enrollment target (62% lower). The listed sponsor is CereVasc, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Hydrocephalus appearing as the primary indexed condition, and to 1 intervention - of which eShunt Implant is the first listed.

NCT05232838 reports 11 study locations spanning 8 distinct geographic areas - top geographies include New York, Connecticut, Florida.

Frequently Asked Questions

What is clinical trial NCT05232838 about?

NCT05232838 is a clinical study titled "US Pilot Study of the CereVasc® eShunt® System in Normal Pressure Hydrocephalus". The eShunt® System is a minimally invasive method of treating communicating hydrocephalus. The eShunt System includes a proprietary eShunt Delivery System and the eShunt Implant, a permanent implant deployed in a minimally invasive, neuro-interventional procedure. The eShunt System is intended to sh...

What is the current status of trial NCT05232838?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 50 participants. The study started on 2022-04-20. Estimated completion is 2030-06-30.

What conditions does trial NCT05232838 study?

This clinical trial studies the following conditions: Hydrocephalus, Hydrocephalus, Normal Pressure.

What interventions are being tested in trial NCT05232838?

The interventions under investigation include: eShunt Implant (DEVICE).

Who is sponsoring clinical trial NCT05232838?

This trial is sponsored by CereVasc, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05232838 being conducted?

This trial has 11 study locations across Connecticut, Florida, Kansas, Kentucky, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hydrocephalus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Hydrocephalus

All registered trials for this condition

Hydrocephalus, Normal Pressure

All registered trials for this condition

Connecticut

All trials with a study site in Connecticut

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.